Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
// Billy Samuel Hill 1, * , Alessandra Pelagalli 1, 2, * , Nunzia Passaro 1 and Antonella Zannetti 1 1 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), Naples, Italy 2 Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, Italy * Authors contributed equally to this work Correspondence to: Antonella Zannetti, email: antonella.zannetti@cnr.it Keywords: mesenchymal stem cells, tumor microenvironment, epithelial-mesenchymal transition, metastatic phenotype Received: February 03, 2017 Accepted: August 04, 2017 Published: August 14, 2017 ABSTRACT Multipotent mesenchymal stem cells (MSCs) are recruited into tumor microenvironment in response to multiple signals produced by cancer cells. Molecules involved in their homing to tumors are the same inflammatory mediators produced by injured tissues: chemokines, cytokines and growth factors. When MSCs arrive into the tumor microenvironment these are “educated” to have pro-metastatic behaviour. Firstly, they promote cancer immunosuppression modulating both innate and adaptive immune systems. Moreover, tumor associated-MSCs trans-differentiating into cancer-associated fibroblasts can induce epithelial-mesenchymal-transition program in tumor cells. This process determinates a more aggressive phenotype of cancer cells by increasing their motility and invasiveness and favoring their dissemination to distant sites. In addition, MSCs are involved in the formation and modelling of pre-metastatic niches creating a supportive environment for colonization of circulating tumor cells. The development of novel therapeutic approaches targeting the different functions of MSCs in promoting tumor progression as well as the mechanisms underlying their activities could enhance the efficacy of conventional and immune anti-cancer therapies. Furthermore, many studies report the use of MSCs engineered to express different genes or as vehicle to specifically deliver novel drugs to tumors exploiting their strong tropism. Importantly, this approach can enhance local therapeutic efficacy and reduce the risk of systemic side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 2×
“Among stromal cells that constitute TME, CAFs are known to play a crucial role in promoting tumor progression [60].”
BackgroundThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487 · cited 1×
“It has been reported the importance of expression and functional activation of a group of EMT-inducing transcription factors (Twist, Snail, Slug, zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2 [81, 94].”
BackgroundHypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages
Kim, J., & Hematti, P. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.004 · Cited by 785
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells
Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008) · Gene Therapy · doi:10.1038/gt.2008.39 · Cited by 579 · cited 13×
“These investigations could provide information for targeting TA-MSCs with therapeutic approaches and eventually for using them as vehicles to deliver specifically in TME anti-cancer agents.”
BackgroundInfluentialKlopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 1×
“Although many studies reported the pro-tumorigenic activity of MSCs many others showed their tumor suppressive properties [8].”
BackgroundQin, Y., Capaldo, C., Gumbiner, B. M., & Macara, I. G. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200506094 · Cited by 285 · cited 1×
“The activation of these transcription factors causes the down-regulation of genes responsible to encode epithelial junction proteins determining a disassembly of adherens junctions, desmosomes, and tight junctions [95].”
BackgroundHung, S.-C., Deng, W.-P., Yang, W. K., Liu, R.-S., Lee, C.-C., Su, T.-C., Lin, R.-J., Yang, D.-M., Chang, C.-W., Chen, W.-H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0876 · Cited by 268
Macrophages modulate the viability and growth of human mesenchymal stem cells
Freytes, D. O., Kang, J. W., Marcos‐Campos, I., & Vunjak‐Novakovic, G. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24357 · Cited by 255 · cited 1×
“In triple negative breast cancer, the cross-talk between tumor cells and MSCs, caused the production of macrophage colonystimulating factor 1 (CSF1) that recruited in the TME, tumor-associated macrophages (TAMs) and myeloidderived suppressor cells (MDSCs) [51].”
BackgroundThe roles of mesenchymal stem cells in tumor inflammatory microenvironment
Sun, Z., Wang, S., & Zhao, R. C. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-14 · Cited by 249 · cited 1×
“A described above, MSCs into tumor sites are modified in TA-MSCs that contribute to generate malignant phenotype also excercising an immunosuppressive funcion [43, 44].”
BackgroundCannito, S., Novo, E., di Bonzo, L. V., Busletta, C., Colombatto, S., & Parola, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2737 · Cited by 239 · cited 1×
“In these last years, research studies on mechanisms underlying tumor progression and acquisition of premetastatic phenotype have demonstrated well that MSCs actively participate in inducing oncogenic EMT (Figure 2) [81, 82].”
BackgroundChaturvedi, P., Gilkes, D. M., Takano, N., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406655111 · Cited by 226
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007) · The FASEB Journal · doi:10.1096/fj.07-8832com · Cited by 222
Recent discoveries concerning the tumor - mesenchymal stem cell interactions
Lazennec, G., & Lam, P. Y. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.10.004 · Cited by 117 · cited 1×
“Many EMT inducible factors have been demonstrated to be produced or secreted by MSCs such as cytokines (IL1, IL6) [87], chemokines (CCL5 , CXCL1, CXCL5, CXCL7 and CXCL8) [88, 89], growth factors (TGF-β, FGF, Hepatocyte growth factor HGF and epidermal growth factor, EGF) [90, 91] as well as hypoxia inducible factors an…”
BackgroundExpression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma
Nouraee, N., Van Roosbroeck, K., Vasei, M., Semnani, S., Samaei, N. M., Naghshvar, F., Omidi, A. A., Calin, G. A., & Mowla, S. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073009 · Cited by 103
Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy
Eliopoulos, N., Francois, M., Boivin, M.-N., Martineau, D., & Galipeau, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0160 · Cited by 90
Fontanella, R., Pelagalli, A., Nardelli, A., D'Alterio, C., Ieranò, C., Cerchia, L., Lucarelli, E., Scala, S., & Zannetti, A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.018 · Cited by 79 · cited 2×
“On this regard, recently we reported that CXCL12/CXCR4 axis is involved in migration and invasion of osteosarcoma and hepatocellular carcinoma cell lines through EMT activation [6].”
BackgroundSelf-citationDuan, X., Guan, H., Cao, Y., & Kleinerman, E. S. (2009) · Cancer · doi:10.1002/cncr.24013 · Cited by 79
Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas
Grisendi, G., Spano, C., D'souza, N., Rasini, V., Veronesi, E., Prapa, M., Petrachi, T., Piccinno, S., Rossignoli, F., Burns, J. S., et al. (2015) · STEM CELLS · doi:10.1002/stem.1903 · Cited by 48
Ramos, T. L., Sánchez-Abarca, L. I., Redondo, A., Hernández-Hernández, Á., Almeida, A. M., Puig, N., Rodríguez, C., Ortega, R., Preciado, S., Rico, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15969 · Cited by 13 · cited 2×
“(2017) reported that the inhibition of Histone deacetylases 8 in MSCs derived from myeloproliferative neoplasms selectively decreases their hematopoietic-supporting ability [9].”
Background
Cited by
Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., Wietek, N., Alsaadi, A., Carrami, E. M., Hu, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0637-x · Cited by 218
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Metadata
- Authors
- Hill, B. S., Pelagalli, A., Passaro, N., & Zannetti, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-08-14
- Volume
- 8
- Issue
- 42
- Pages
- 73296-73311
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2746059023
- Cited by
- 104
- References
- 28
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.